Show simple item record

dc.contributor.advisorReddy, Kaladhar
dc.contributor.authorBusch, Stephanie M.
dc.date.accessioned2008-03-13T15:04:07Z
dc.date.available2008-03-13T15:04:07Z
dc.date.copyright2004-01-01
dc.date.issued2004
dc.identifier.urihttp://hdl.handle.net/10920/4378
dc.description1 broadside : ill.
dc.descriptionDiebold Scholar
dc.description.abstractBreast cancer is one of the most common forms of cancer in women in the western world. Estrogen has been shown to play a key role in the development and progression of breast cancer with 2/3 of tumors expressing estrogen receptor-α (ERα). Under prolonged exposure to endogenous estrogens, breast tumors develop. Over the past two decades, Tamoxifen has been the most effective anti-estrogen therapy in the treatment of ERα-positive breast cancer (Osbourne et al., 1998). Unfortunately, patients eventually acquire resistance to Tamoxifen within four to eight years. Previous research has shown activation of PI3K/AKT2 and Ras/MAPK signaling pathways lead to tamoxifen resistance (Atanaskova, N et al., 2002). The purpose of this project is to establish the role of the PI3K/AKT2 pathway and its downstream signaling molecules, specifically mTOR, in anti-estrogen treatment. Inhibition of mTOR signaling by rapamycin was done to determine if p70 S6 Kinase and 4E-BP1 activation could be inhibited. In turn, cell cycle progression and tumor growth would, in theory, stop; therefore, tamoxifen resistance could be reversed in tumor cells that overexpress activated AKT2. Western blot analyses were conducted to visualize phosphorylated levels of 4E-BP1 and p70 S6 Kinase in EGFR/MCF-7 and MCF-7 cells. Overall, this research has implications for improving estrogen-mediated breast cancer treatment with Tamoxifen.en
dc.description.sponsorshipKalamazoo College. Department of Biology. Diebold Symposium, 2004
dc.description.sponsorshipWayne State University, Detroit. School of Medicine.
dc.description.tableofcontentsIntroduction -- Materials and methods -- Conclusions -- Future directions -- Acknowledgments
dc.language.isoen_USen
dc.publisherKalamazoo College
dc.subject.lcshBreast -- Cancer -- Research
dc.titleThe Role of the PI3K/AKT2 Pathway in Anti-Estrogen Resistant Breast Canceren
dc.typePresentationen


Files in this item

Thumbnail

This item appears in the following Collection(s)

  • Diebold Symposium Posters and Schedules [320]
    Poster and oral presentations by senior biology majors that include the results of their Senior Individualized Projects (SIPs) at the Diebold Symposium. Abstracts are generally available to the public, but PDF files are available only to current Kalamazoo College students, faculty, and staff.

Show simple item record